寡转移性激素敏感性前列腺癌索引转移灶的进展:对转移灶导向治疗的启示
本研究为单中心回顾性研究,纳入79例新发寡转移性激素敏感性前列腺癌(omHSPC)患者,均接受全身治疗和前列腺放疗,生化进展时行PSMA-PET/CT再分期。中位随访39个月,15例(19%)出现疾病进展,其中11/15(73%)在索引寡转移灶处进展,7例另有新发转移。结论提示索引转移灶高进展比例支持转移灶导向局部消融的潜在获益。
要点
- 新发omHSPC经标准全身治疗和前列腺放疗后,索引寡转移灶是主要进展部位。
- 生化进展再分期时,73%(11/15)进展患者存在索引转移灶进展。
- 索引转移灶高进展率提示转移灶导向治疗可能带来局部消融获益。
核心结论
- 索引寡转移灶的高进展比例支持对新发omHSPC行转移灶导向治疗的潜在获益。
研究设计与样本
- 单中心研究,纳入2015至2024年79例新发omHSPC患者(M1a=22,M1b=57),均接受全身治疗和前列腺放疗,生化进展时行PSMA-PET/CT再分期。
主要发现
- 中位随访39个月(IQR 28-69),15例(19%)出现疾病进展。
- 再分期PSMA-PET/CT显示11/15例(73%)索引寡转移灶进展,其中7例另有新发转移。
临床怎么用
- 对新发omHSPC行标准治疗时,应关注索引寡转移灶的局部进展风险,可考虑转移灶导向治疗。
局限性
- 单中心回顾性设计,样本量有限(79例),进展事件较少(15例)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: For de-novo oligometastatic prostate cancer (omHSPC) treated with standard of care androgen suppression and prostate radiotherapy, the patterns of progression vis-a-vis index metastatic sites are not well understood. METHODS: This single-centre study included patients with de-novo omHSPC (CHAARTED criteria) staged with a PSMA-PET/CT scan at diagnosis, treated with systemic therapy and prostate radiotherapy, and re-staged with PSMA-PET/CT at biochemical progression. Disease status at index oligometastases was noted at progression. RESULTS: From 2015 to 2024, 79 patients with omHSPC were found eligible (M1a = 22, M1b = 57). Over a median follow-up of 39 months (IQR 28-69), 15 patients (19%) had disease progression. Restaging PSMA-PET/CT revealed progression of the index oligometastases for 11/15 patients (73%), with additional metastases in 7 of these. CONCLUSION: The high proportion of progression at the index oligometastases supports the potential benefit of metastasis-directed therapy for local ablation.
引用
- Verma P, Maitre P, Krishnasamy GS, et al. Progression of index metastases in oligometastatic hormone-sensitive prostate cancer: implications for metastases directed therapy? Prostate Cancer Prostatic Dis. 2025. PMID: 41372716. doi:10.1038/s41391-025-01056-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。